 Caffeine
"Caffeine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes SMOOTH MUSCLE, stimulates CARDIAC MUSCLE, stimulates DIURESIS, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide PHOSPHODIESTERASES, antagonism of ADENOSINE RECEPTORS, and modulation of intracellular calcium handling.
| Descriptor ID |
D002110
|
| MeSH Number(s) |
D03.132.960.175 D03.438.759.758.824.175
|
| Concept/Terms |
Vivarin- Vivarin
- GlaxoSmithKline Brand of Caffeine
Dexitac- Dexitac
- Republic Drug Brand of Caffeine
No Doz- No Doz
- Bristol-Myers Squibb Brand of Caffeine
Quick-Pep- Quick-Pep
- Thompson Brand 2 of Caffeine
|
Below are MeSH descriptors whose meaning is more general than "Caffeine".
Below are MeSH descriptors whose meaning is more specific than "Caffeine".
This graph shows the total number of publications written about "Caffeine" by people in this website by year, and whether "Caffeine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1982 | 0 | 1 | 1 | | 1985 | 0 | 1 | 1 | | 1986 | 0 | 1 | 1 | | 1990 | 1 | 0 | 1 | | 1991 | 0 | 1 | 1 | | 1996 | 2 | 2 | 4 | | 1997 | 0 | 1 | 1 | | 1998 | 1 | 2 | 3 | | 1999 | 0 | 1 | 1 | | 2000 | 0 | 5 | 5 | | 2001 | 0 | 1 | 1 | | 2002 | 1 | 0 | 1 | | 2003 | 0 | 6 | 6 | | 2004 | 1 | 0 | 1 | | 2005 | 0 | 2 | 2 | | 2006 | 1 | 1 | 2 | | 2008 | 1 | 1 | 2 | | 2009 | 1 | 1 | 2 | | 2010 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2012 | 1 | 3 | 4 | | 2013 | 0 | 1 | 1 | | 2014 | 1 | 1 | 2 | | 2015 | 3 | 0 | 3 | | 2016 | 1 | 0 | 1 | | 2018 | 3 | 0 | 3 | | 2020 | 1 | 2 | 3 | | 2021 | 1 | 0 | 1 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Caffeine" by people in Profiles.
-
Cornelis MC, Bennett DA, Weintraub S, Schneider JA, Morris MC. Caffeine Consumption and Dementia: Are Lewy Bodies the Link? Ann Neurol. 2022 06; 91(6):834-846.
-
Reuter SE, Schultz HB, Ward MB, Grant CL, Paech GM, Banks S, Evans AM. The effect of high-dose, short-term caffeine intake on the renal clearance of calcium, sodium and creatinine in healthy adults. Br J Clin Pharmacol. 2021 11; 87(11):4461-4466.
-
Sholtes D, Kravitz HM, Deka A, Westrick J, Fogg LF, Gottlieb M. Optimising sleep and performance during night float: A systematic review of evidence and implications for graduate medical education trainees. J Sleep Res. 2021 08; 30(4):e13212.
-
Erwin JA, Skeiky L, Satterfield BC, Paech GM, Layton ME, Van Dongen HPA, Hansen DA. Robustness of inter-individual differences in slow wave sleep for daytime sleep periods after total sleep deprivation with or without caffeine administration: potential implications for around-the-clock operations. Chronobiol Int. 2020 Sep-Oct; 37(9-10):1465-1468.
-
Ibarra Moreno CA, Kraeva N, Zvaritch E, Figueroa L, Rios E, Biesecker L, Van Petegem F, Hopkins PM, Riazi S. A multi-dimensional analysis of genotype-phenotype discordance in malignant hyperthermia susceptibility. Br J Anaesth. 2020 12; 125(6):995-1001.
-
Figueroa L, Kraeva N, Manno C, Toro S, Ríos E, Riazi S. Abnormal calcium signalling and the caffeine-halothane contracture test. Br J Anaesth. 2019 Jan; 122(1):32-41.
-
Pajcin M, White JM, Banks S, Dorrian J, Paech GM, Grant CL, Johnson K, Tooley K, Aidman E, Fidock J, Kamimori GH, Della Vedova CB. Effects of strategic early-morning caffeine gum administration on association between salivary alpha-amylase and neurobehavioural performance during 50?h of sleep deprivation. Accid Anal Prev. 2019 May; 126:160-172.
-
Grant CL, Coates AM, Dorrian J, Paech GM, Pajcin M, Della Vedova C, Johnson K, Kamimori GH, Fidock J, Aidman E, Banks S. The impact of caffeine consumption during 50 hr of extended wakefulness on glucose metabolism, self-reported hunger and mood state. J Sleep Res. 2018 10; 27(5):e12681.
-
Morris MC. Caffeine Intake and Dementia Risk-A Health Benefit From One of Life's Simple Pleasures? J Gerontol A Biol Sci Med Sci. 2016 12; 71(12):1595.
-
Paech GM, Banks S, Pajcin M, Grant C, Johnson K, Kamimori GH, Vedova CB. Caffeine administration at night during extended wakefulness effectively mitigates performance impairment but not subjective assessments of fatigue and sleepiness. Pharmacol Biochem Behav. 2016 06; 145:27-32.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|